Phase II trial of docetaxel therapy in patients with advanced hepatocellular carcinoma

Oncology

Volumn 70, Issue 2, 2006, Pages 154-158

  Hebbar, Mohamed ^a   Ernst, Olivier ^a   Cattan, Stéphane ^a   Dominguez, Sophie ^b   Oprea, Corina ^c   Mathurin, Philippe ^a   Triboulet, Jean Pierre ^a   Paris, Jean Claude ^a   Pruvot, François René ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b CENTRE OSCAR LAMBRET   (France)

^c SANOFI   (France)

Author keywords

Docetaxel; Hepatocellular carcinoma

Indexed keywords

AMINOTRANSFERASE; DOCETAXEL; DOXORUBICIN;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTHRALGIA; ARTICLE; CANCER RELAPSE; CANCER SURVIVAL; CHEMOEMBOLIZATION; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; EDEMA; FATIGUE; FEMALE; HUMAN; HYPERBILIRUBINEMIA; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER RESECTION; LIVER TRANSPLANTATION; MALE; MUCOSA INFLAMMATION; MYALGIA; NAUSEA; NEUROPATHY; NEUTROPENIA; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIOLOGY; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA, HEPATOCELLULAR; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; SURVIVAL ANALYSIS; TAXOIDS; TREATMENT FAILURE;

EID: 33646779207     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000093007     Document Type: Article

References (25)

1. El-Serag HB: Epidemiology of hepatocellular carcinoma (review). Clin Liver Dis 2001;5:87-107.
2. Nowak AK, Chow PK, Findlay M: Systemic therapy for advanced hepatocellular carcinoma: a review. Eur J Cancer 2004;40:1474-1484.
3. Mathurin P, Rixe O, Carbonell N, Bernard B, Cluzel P, Bellin MF, Khayat D, Opolon P, Poynard T: Review article: overview of medical treatments in unresectable hepatocellular carcinoma - an impossible meta-analysis? Aliment Pharmacol Ther 1998;12:111-126.
4. Coleman RE, Howell A, Eggleton SP, Maling SJ, Miles DW: Phase II study of docetaxel in patients with liver metastases from breast cancer. UK study group. Ann Oncol 2000;11:541-546.
5. Lin HL, Liu TY, Chau GY, Lui WY, Chi CW: Comparison of 2-methoxyestradiol-induced, docetaxel-induced, and paclitaxel-induced apoptosis in hepatoma cells and its correlation with reactive oxygen species. Cancer 2000;89:983-994.
6. Zhang H, Ozaki I, Mizuta T, Matsuhashi S, Yoshimura T, Hisatomi A, Tadano J, Sakai T, Yamamoto K: Beta 1-integrin protects hepatoma cells from chemotherapy induced apoptosis via a mitogen-activated protein kinase dependent pathway. Cancer 2002,95:896-906.
7. Geng CX, Zeng ZC, Wang JY: Docetaxel inhibits SMMC-7721 human hepatocellular carcinoma cells growth and induces apoptosis. World J Gastroenterol 2003;9:696-700.
8. Sutter AP, Maaser K, Grabowski P, Bradacs G, Vormbrock K, Hopfner M, Krahn A, Heine B, Stein H, Somasundaram R, Schuppan D, Zeitz M, Scherubl H: Peripheral benzodiazepine receptor ligands induce apoptosis and cell cycle arrest in human hepatocellular carcinoma cells and enhance chemosensitivity to paclitaxel, docetaxel, doxorubicin and the Bcl-2 inhibitor HA14-1. J Hepatol 2004;41:799-807.
9. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216.
10. Olweny CL, Katongole-Mbidde E, Bahendeka S, Otim D, Mugerwa J, Kyalwazi SK: Further experience in treating patients with hepatocellular carcinoma in Uganda. Cancer 1980;46:2717-2722.
11. Olweny CL, Toya T, Katongole-Mbidde E, Mugerwa J, Kyalwazi SK, Cohen H: Treatment of hepatocellular carcinoma with Adriamycin. Preliminary communication. Cancer 1975;36:1250-1257.
12. Llovet JM: Updated treatment approach to hepatocellular carcinoma. J Gastroenterol 2005;40:225-235.
13. O'Reilly EM, Stuart KE, Sanz-Altamira PM, et al: A phase II study of irinotecan in patients with advanced hepatocellular carcinoma. Cancer 2001;91:101-105.
14. Wall JG, Benedetti JK, O'Rourke MA, Natale RB, Macdonald JS: Phase II trial to topotecan in hepatocellular carcinoma: a Southwest Oncology Group study. Invest New Drugs 1997;15:257-260.
15. Ulrich-Pur H, Kornek GV, Fiebiger W, Schull B, Raderer M, Scheithauer W: Treatment of advanced hepatocellular carcinoma with bi-weekly high-dose gemcitabine. Oncology 2001;60:313-315.
16. Lencioni M, Falcone A, Allegrini G, Pfanner E, Masi G, Brunetti I, Di Marsico R, Fontana E, Orlandini C, Stampino CG, Bartolozzi C, Conte PF: Oral doxifluridine in advanced hepatocellular carcinoma: a phase II study. Oncology 2000;59:204-209.
17. Chao Y, Chan WK, Birkhofer MJ, Hu OY, Wang SS, Huang YS, Liu M, Whang-Peng J, Chi KH, Lui WY, Lee SD: Phase II and pharmacokinetic study of paclitaxel therapy for unresectable hepatocellular carcinoma patients. Br J Cancer 1998;78:34-39.
18. Ikeda M, Okusaka T, Ueno H, Takezako Y, Morizane C: A phase II trial of continuous infusion of 5-fluorouracil, mitoxantrone, and cisplatin for metastatic hepatocellular carcinoma. Cancer 2005;103:756-762.
19. Taieb J, Bonyhay L, Golli L, Ducreux M, Boleslawski E, Tigaud JM, de Baere T, Mansourbakht T, Delgado MA, Hannoun L, Poynard T, Boige V: Gemcitabine plus oxaliplatin for patients with advanced hepatocellular carcinoma using two different schedules. Cancer 2003;98:2664-2670.
20. Ishikawa T, Ichida T, Yokoyama J, Matsuda Y, Watanabe T, Asakura H: Complete disappearance of pulmonary metastases in a case of hepatocellular carcinoma treated with docetaxel-based systemic chemotherapy. J Gastroenterol Hepatol 2004;19:1423-1426.
21. Ryan DP, Lynch TJ, Grossbard ML, Seiden MV, Fuchs CS, Grenon N, Baccala P, Berg D, Finkelstein D, Mayer RJ, Clark JW: A phase I study of gemcitabine and docetaxel in patients with metastatic solid tumors. Cancer 2000;88:180-185.
22. Donelli MG, Zucchetti M, Munzone E, D'Incalci M, Crosignani A: Pharmacokinetics of anticancer agents in patients with impaired liver function. Eur J Cancer 1998;34:33-46.
23. Clarke SJ, Rivory LP: Clinical pharmacokinetics of docetaxel. Clin Pharmacokinet 1999;36:99-114.
24. Vogel CL, Bayley AC, Brooker RJ, Anthony PP, Ziegler JL: A phase II study of Adriamycin (NSC 123127) in patients with hepatocellular carcinoma from Zambia and the United States. Cancer 1977;39:1923-1929.
25. Cusnir M, Patt YZ: Novel systemic therapy options for hepatocellular carcinoma. Cancer J 2004;10:97-103.